Quale sarebbe il prezzo per Generate Biomedicines, Inc. (GENB)

Il prezzo per Generate Biomedicines, Inc. (GENB) è $16.14

Qual è la capitalizzazione di mercato per Generate Biomedicines, Inc. (GENB)

La capitalizzazione di mercato per Generate Biomedicines, Inc. (GENB) è $2.07B

Utili di Generate Biomedicines, Inc. (GENB)

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Anno	Utile	Cambia
Non abbastanza dati per le date fornite.

Anno

Utile

Cambia

Non abbastanza dati per le date fornite.

Azienda	Utile	Differenza negli utili	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Azienda

Utile

Differenza negli utili

Il paese